Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers.

Heart --- Cancer --- Diseases --- Etiology. --- Treatment --- Complications. --- Complications and sequelae --- Cardiovascular system --- Cardiovascular Diseases --- Heart Diseases --- Neoplasms --- Diseases. --- therapy --- Cardiac Diseases --- Cardiac Disorders --- Heart Disorders --- Cardiac Disease --- Cardiac Disorder --- Heart Disease --- Heart Disorder --- Cardiology --- Cardiovascular Disease --- Disease, Cardiovascular --- Diseases, Cardiovascular --- Cardiac diseases --- Heart diseases --- Cardiovascular diseases --- Adverse Cardiac Event --- Cardiac Events --- Major Adverse Cardiac Events --- Adverse Cardiac Events --- Cardiac Event --- Cardiac Event, Adverse --- Cardiac Events, Adverse --- Event, Cardiac --- Cardiotoxicity --- Cardio-Oncology --- Cardiotoxicity. --- Cardio-Oncology. --- Cardiovascular Diseases. --- Heart Diseases. --- therapy.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. [...] Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.

Cardiovascular toxicology. --- Cardiotoxicity. --- Drug-Related Side Effects and Adverse Reactions. --- Antineoplastic Agents. --- Radiotherapy --- Anticancer Agents --- Antineoplastic Drugs --- Antineoplastics --- Antitumor Agents --- Antitumor Drugs --- Cancer Chemotherapy Agents --- Cancer Chemotherapy Drugs --- Chemotherapeutic Anticancer Agents --- Chemotherapeutic Anticancer Drug --- Anticancer Agent --- Antineoplastic --- Antineoplastic Agent --- Antineoplastic Drug --- Antitumor Agent --- Antitumor Drug --- Cancer Chemotherapy Agent --- Cancer Chemotherapy Drug --- Agent, Anticancer --- Agent, Antineoplastic --- Agent, Antitumor --- Agent, Cancer Chemotherapy --- Agents, Anticancer --- Agents, Antineoplastic --- Agents, Antitumor --- Agents, Cancer Chemotherapy --- Agents, Chemotherapeutic Anticancer --- Chemotherapy Agent, Cancer --- Chemotherapy Agents, Cancer --- Chemotherapy Drug, Cancer --- Chemotherapy Drugs, Cancer --- Drug, Antineoplastic --- Drug, Antitumor --- Drug, Cancer Chemotherapy --- Drug, Chemotherapeutic Anticancer --- Drugs, Antineoplastic --- Drugs, Antitumor --- Drugs, Cancer Chemotherapy --- Cytotoxins --- Interferon Inducers --- Anticarcinogenic Agents --- Adverse Drug Event --- Adverse Drug Reaction --- Drug Side Effects --- Drug Toxicity --- Side Effects of Drugs --- Toxicity, Drug --- Adverse Drug Events --- Adverse Drug Reactions --- Drug Event, Adverse --- Drug Events, Adverse --- Drug Reaction, Adverse --- Drug Reactions, Adverse --- Drug Related Side Effects and Adverse Reactions --- Drug Side Effect --- Drug Toxicities --- Effects, Drug Side --- Reactions, Adverse Drug --- Side Effect, Drug --- Side Effects, Drug --- Toxicities, Drug --- Drug Therapy --- Pharmaceutical Preparations --- Contraindications, Drug --- Drug Interactions --- Clinical Trials, Phase IV as Topic --- Cardiac Toxicity --- Cardiac Toxicities --- Cardiotoxicities --- Toxicity, Cardiac --- Cardiovascular toxicity --- Toxicology --- adverse effects. --- adverse effects --- toxicity --- Heart --- Effect of drugs on. --- Cardiovascular pharmacology --- Drug effects --- Cardiotoxicity --- Drug-Related Side Effects and Adverse Reactions --- Antineoplastic Agents --- adverse effects ǂ0 (DNLM)D011878Q000009

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell–cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- n/a --- cell-cell contact

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Creatine plays a critical role in cellular metabolism, primarily by binding with phosphate to form phosphocreatine (PCr) as well as shuttling high-energy phosphate compounds in and out of the mitochondria for metabolism. Increasing the dietary availability of creatine increases the tissue and cellular availability of PCr, and thereby enhances the ability to maintain high-energy states during intense exercise. For this reason, creatine monohydrate has been extensively studied as an ergogenic aid for exercise, training, and sport. Limitations in the ability to synthesize creatine and transport and/or store dietary creatine can impair metabolism and is a contributor to several disease states. Additionally, creatine provides an important source of energy during metabolically stressed states, particularly when oxygen availability is limited. Thus, researchers have assessed the role of creatine supplementation on health throughout the lifespan, as well as whether creatine availability may improve disease management and/or therapeutic outcomes. This book provides a comprehensive overview of scientific and medical evidence related to creatine's role in metabolism, health throughout the lifespan, and our current understanding of how creatine can promote brain, heart, vascular and immune health; reduce the severity of musculoskeletal and brain injury; and may provide therapeutic benefits in glucose management and diabetes, cancer therapy, inflammatory bowel disease, and post-viral fatigue.

ergogenic aids --- cellular metabolism --- phosphagens --- sarcopenia --- cognition --- diabetes --- creatine synthesis deficiencies --- concussion --- traumatic brain injury --- spinal cord injury --- muscle atrophy --- rehabilitation --- pregnancy --- immunity --- anti-inflammatory --- antioxidant --- anticancer --- creatine --- nutritional supplements --- fertility --- newborn --- development --- brain injury --- post-viral fatigue syndrome --- chronic fatigue syndrome --- GAA --- creatine kinase --- dietary supplements --- exercise --- skeletal muscle --- glycemic control --- type 2 diabetes mellitus --- phosphorylcreatine --- dietary supplement --- ergogenic aid --- youth --- athletes --- osteoporosis --- osteosarcopenia --- frailty --- cachexia --- innate immunity --- adaptive immunity --- inflammation --- macrophage polarization --- cytotoxic T cells --- toll-like receptors --- vascular pathology --- cardiovascular disease --- oxidative stress --- vascular health --- female --- menstrual cycle --- hormones --- exercise performance --- menopause --- mood --- children --- height --- BMI-for-age --- stature-for-age --- growth --- phosphocreatine --- creatine transporter --- supplementation --- treatment --- heart --- heart failure --- ischemia --- myocardial infarction --- anthracycline --- cardiac toxicity --- energy metabolism --- cell survival --- bioinformatics --- systems biology --- cellular allostasis --- dynamic biosensor --- pleiotropic effects of creatine (Cr) supplementation --- inflammatory bowel diseases (IBD) --- ulcerative colitis --- Crohn’s disease --- creatine kinase (CK) --- phosphocreatine (PCr) --- creatine transporter (CrT) --- intestinal epithelial cell protection --- intestinal tissue protection --- creatine perfusion --- organ transplantation --- Adenosine mono-phosphate (AMP) --- activated protein kinase (AMPK) --- liver kinase B1 (LKB1) --- mitochondrial permeability transition pore (mPTP) --- reactive oxygen species (ROS) --- glucose transporter (GLUT) --- T cell antitumor immunity --- metabolic regulator --- cancer immunotherapy --- supplements --- muscle damage --- recovery --- immobilization --- atrophy --- muscular dystrophy --- amyotrophic lateral sclerosis --- Parkinson’s Disease --- cardiopulmonary disease --- mitochondrial cytopathy --- hypertrophy --- athletic performance --- weightlifting --- resistance exercise --- training --- muscular power --- muscular adaptation --- muscle fatigue --- adipose tissue --- muscle strength --- physiological adaptation --- mitochondria --- thermogenesis --- MAP kinase signaling system --- sodium-chloride-dependent neurotransmitter symporters --- signal transduction --- intradialytic creatine supplementation --- hemodialysis --- muscle --- protein energy wasting --- clinical trial --- muscle weakness --- chronic fatigue --- cognitive impairment --- depression --- anemia --- resistance training --- sports nutrition --- strength --- toxicity --- methylation --- hyperhomocysteinemia --- neuromodulation --- MCDA --- mitochondriopathia --- cardiac infarction --- long COVID --- hypoxia --- stroke --- neurodegenerative diseases --- noncommunicable disease --- adenosine 5′-monopnophosphate-activated protein kinase --- anthracyclines --- creatine supplementation --- cardiac signaling --- cardiotoxicity --- doxorubicin --- soy --- vegetarian/vegan diet --- amino acids --- dietary ingredients --- performance